Login to Your Account



Astrazeneca, Chinese Future Industry Investment Fund launch JV for novel drugs

By David Ho
Staff Writer

Wednesday, December 6, 2017

HONG KONG – Astrazeneca plc has teamed up with the Chinese Future Industry Investment Fund (FIIF) to form a joint venture in China for drug development via an equally owned, stand-alone company named Dizal Pharmaceutical.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription